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INHIBITION OF REACTIVE OXYGEN
SPECIES AND PROTECTION OF
MAMMALIAN CELLS

metabolic insults from reactive oxygen species originating
within or outside of the cells. These diseases include all
forms of blindness whether hereditary, light-induced, or
physical damage such as occurs in retinal detachment. In
addition, damage due to ageing, stroke, cardiac infarction,
burns, etc, which proceed through reactive oxygen species,
can be addressed with the nanoceria particles of the present
invention.
The present invention promotes a longer lifespan for
retinal neurons. The greatest benefit of the nanoceria is its
ability to get inside the cells and provide protection from
reactive oxygen species (ROS); other body systems and
tissues can also be protected from damage due to ROS.

This is a Divisional of application Ser. No. 11/412,665
filed Apr. 27, 2006 which claims the benefit of priority to
U.S. Provisional Patent Application No. 60/676,043 filed
Apr. 29, 2005 and claims benefit of U.S. Provisional Patent
Application No. 60/716,630 filed Sep. 13, 2005.
10

FIELD OF THE INVENTION
This invention relates to biological uses of nanoceria
particles, and in particular to methods and compos1t10ns
useful for neuronal protection in retinal cells in vitro and the
protection of mammalian cells from reactive oxygen species
in vivo and is supported in part by funding from the National
Science Foundation and National Institutes of Health under
the Contract numbers: P20 RR! 7703, FY014427, FY13050,
and FY12190.
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20

BACKGROUND AND PRIOR ART
Cerium is a silvery metallic element, belonging to the
lanthanide group. Cerium Oxide (Ce0 2 ) is used in precision
polishing and lapping applications. Ultra fine nano-size
cerium oxide, less than 10 nanometers, is more efficient for
coating purposes. Recently, it was reported by B. Rzigalinski
et al. that nanoparticles prolong the life of cortical neurons
in culture 4 fold over the cells without treatment; decreased
the intracellular Ca2+ concentration and prevented UV
damage of cortical neurons. See B. Rzigalinski et al.,
"Cerium Oxide Nanoparticles Extend Cell Longevity and
Act as Free Radical Scavengers" at website http://www.med.miami.edu/mnbws/Rzigalinskil 12.html. Based on its
chemical characteristics, this effect is partially due to a
decrease of reactive oxygen species (ROS).
Retina tissue generates a large amount of ROS which are
involved in light-induced retina degeneration and age-related macular degeneration (AMD). The present invention
tests the hypothesis that nanoparticles can promote the
lifespan of retinal neurons in culture and protect them from
apoptosis induced by hydrogen peroxide (H 2 0 2 ) in vitro by
decreasing the intracellular concentration of reactive oxygen
species.
In 2004, T. H. Margrain et al. discuss the state of research
in the treatment of age-related macular degeneration in
Progress in Retinal and Eve Research, 2004, 23: 523-531,
"Do Blue Light Filters Confer Protection Against AgeRelated Macular Degeneration?" The problem of apoptosis
in the body is discussed in an article by P. Moongkarndi et
al. in "Antiproliferation, Antioxidation and Induction of
Apoptosis by Garcinia Mangostana (Mangosteen) on
SKBR3 Human Breast Cancer Cell Line", Jl. ofEthnopharmacology, 2004, 90: 161-166.
Often persons suffering from light-induced retina degeneration and age-related macular degeneration (AMD) are
without satisfactory remedies to prevent the eventual outcome of blindness. There are some proteins available for
neuronal protection of retinal cells, however, they are big
molecules and over time their effect may fade away.
It is desirable to find reliable solutions to prolong the
lifespan of retinal neurons so that blindness is avoided for
persons with retina degeneration and AMD.
In addition to diseases of the eye, many human diseases
are due to the death of cells in specific tissues or organs. The
majority of those diseases are due to accumulation of
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SUMMARY OF THE INVENTION
A primary objective of the present invention is to promote
the lifespan of retinal neurons in culture.
A secondary objective of the present invention is to
protect retinal neurons from apoptosis induced by hydrogen
peroxide (H 2 0 2 ) in vitro.
A third objective of the present invention is to protect
retinal neurons from apoptosis induced by reactive oxygen
species in vivo.
A fourth objective of the present invention is to inhibit the
rise in the intracellular concentration of reactive oxygen
species (ROS).
A fifth objective of the present invention is to provide
method for inhibiting apoptosis induced by H 2 0 2 of retinal
neurons in vitro in a dose and time dependent manner.
A sixth objective of the present invention is to provide
method for inhibiting apoptosis induced by reactive oxygen
species in retinal neurons in vivo in a dose and time
dependent manner.
A seventh objective of the present invention is to provide
a method for preventing an increase in the intracellular
reactive oxygen species (ROS) in a dose and time dependent
manner.
An eighth objective of the-present invention is to manufacture and modify cerium oxide (Ce0 2 ) nanoparticles for
effective use in neuronal protection in retinal cells.
A ninth objective of the present invention is to manufacture and modify cerium oxide (Ce0 2 ) nanoparticles for
effective use in mammalian cells in vivo to inhibit damage
caused by reactive oxygen species (ROS).
A preferred composition for promoting longevity of retinal neurons includes at least one of CeO.sub.nl wherein
0<n1<2, and 0<n2<3 in the form of ultra-fine particles. The
preferred ultra-fine particles have a diameter in a range
between approximately 1 nanometer (nm) and approximately 10 nm and the preferred CeO.sub.nl is further
defined as nl equals approximately 2.
A preferred composition for inhibiting apoptosis induced
by hydrogen peroxide oxidation of retinal neurons includes
at least one ofCeO.sub.nl wherein 0<n1<2, and 0<n2<3 in
the form of ultra-fine particles. The preferred ultra-fine
particles have a diameter in a range between approximately
1 nanometer (nm) and approximately 10 nm and the preferred CeO.sub.nl is further defined as nl equals approximately 2.
A preferred composition for inhibiting apoptosis of retinal
neurons in a dose and time dependent manner includes at
least one of CeO.sub.nl wherein O<nl <2, and 0<n2<3 in the
form of ultra-fine particles. The preferred ultra-fine particles
have a diameter in a range between approximately 1 nanometer (nm) and approximately 10 nm and the preferred
CeO.sub.nl is further defined as nl equals approximately 2.

US 7,347,987 B2
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A more preferred composition that decreases the concentration of intracellular reactive oxygen species (ROS)
includes at least one of CeO.sub.nl wherein O<nl <2, and
0<n2<3 in the form of ultra-fine particles. The more preferred composition is used in the treatment of diseases of the
retina selected from the group consisting of light-induced
retina degeneration and age-related macular degeneration,
and is also used in vivo for the treatment of diseases in
mammalian cells to inhibit damage caused by reactive
oxygen species (ROS).
The mammalian cells that can be treated by the composition of the present invention, include, but are not limited
to, retinal neurons, brain cells, heart cells, skin cells, liver
cells, kidney cells and peripheral nervous system cells.
A preferred method for promoting longevity of retinal
neurons includes preparing ultra-fine particles of at least one
ofCeO.sub.nl wherein O<nl <2, and 0<n2<3 in a preselected
concentration, and adding the preselected concentration of
CeO.sub.nl wherein O<nl <2, and 0<n2<3 to primary retinal
neurons. The preferred ultra-fine particles have a diameter in
a range between approximately 1 nanometer (nm) and
approximately 10 nm and the CeO.sub.nl is further defined
as nl equals approximately 2. The preferred preselected
concentrations of Ce0 2 are in a range between approximately 3 nanomolar (nM) and approximately fifty nanomolar (nM), more preferably in a range between approximately
3 nanomolar (nM) and approximately twenty nanomolar
(nM).
It is also preferred that the preselected concentrations of
Ce0 2 are added to primary retinal neurons in vitro and/or
administered to mammalian cells in vivo to protect the
mammalian body system from damage to any tissue due to
reactive oxygen species (ROS).
Further objects and advantages of the present invention
will be apparent from the following detailed description of
a presently preferred embodiment which is illustrated schematically in the accompanying drawings.

FIG. 4G is a flow cytometry plot ofretinal neurons treated
with 20 nM cerium oxide in the presence of 100 micromoles
(µM) hydrogen peroxide.
FIG. 4H is a flow cytometry plot ofretinal neurons treated
with 20 nM cerium oxide. FIG. 5 shows relative viable
retinal neurons with and without incubation of different
concentrations of cerium oxide nanoparticles for time periods between approximately 12 hours and approximately 96
hours.
FIG. 6 shows the initial cerium oxide nanoparticle treatments, hydrogen peroxide and DCFH-DA incubation, and
time line of exposure.
FIG. 7A is a graph of the intracellular level of reactive
oxygen species (ROS) of retinal neurons after 30 minutes
incubation with cerium oxide nanoparticles.
FIG. 7B is a graph of the intracellular level of reactive
oxygen species (ROS) of retinal neurons after 12 hours
incubation with cerium oxide nanoparticles.
FIG. 7C is a graph of the intracellular level of reactive
oxygen species (ROS) of retinal neurons after 24 hours
incubation with cerium oxide nanoparticles.
FIG. 7D is a graph of the intracellular level of reactive
oxygen species (ROS) of retinal neurons after 96 hours
incubation with cerium oxide nanoparticles.

10

15

20

25

DESCRIPTION OF THE PREFERRED
EMBODIMENTS
30

35

BRIEF DESCRIPTION OF THE FIGURES
40

FIG. 1 is a timeline of exposure of a primary retinal
neuron culture to treatment with cerium oxide nanoparticles.
FIG. 2 is a graph showing the percentage of apoptotic
retinal neurons in culture with and without 5 nanomoles
(nM) cerium oxide nanoparticle treatment at different time
points.
FIG. 3 shows the initial cerium oxide nanoparticle treatments followed by hydrogen peroxide incubation, and time
line of exposure.
FIG. 4A is a flow cytometry plot of the control sample of
primary retinal neurons with no cerium oxide nanoparticle
treatments and no hydrogen peroxide incubation.
FIG. 4B is a flow cytometry plot of retinal neurons in the
presence of 100 micromoles (µM) hydrogen peroxide.
FIG. 4C is. a flow cytometry plot of retinal neurons
treated with 1 nM cerium oxide in the presence of 100
micromoles (µM) hydrogen peroxide.
FIG. 4D is a flow cytometry plot ofretinal neurons treated
with 3 nM cerium oxide in the presence of 100 micromoles
(µM) hydrogen peroxide.
FIG. 4E is a flow cytometry plot ofretinal neurons treated
with 5 nM cerium oxide in the presence of 100 micromoles
(µM) hydrogen peroxide.
FIG. 4F is a flow cytometry plot of retinal neurons treated
with 10 nM cerium oxide in the presence of 100 micromoles
(µM) hydrogen peroxide.
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Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
particular arrangements shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
The present invention has two embodiments describing in
detail the in vitro and in vivo treatment of mammalian cells
with ultra fine nano-size cerium oxide particles, less than 10
nanometers in diameter, to protect the "body system" from
damage to any tissue due to reactive oxygen species (ROS).
Hydrogen peroxide (H 2 0 2 ) is one of many reactive oxygen species. In the present invention, H 2 0 2 is added directly
to cultures for the in vitro treatments. H 2 0 2 is not added to
the live tissue samples, since H 2 0 2 is one of the ROS
products of light damage. The discussion below confirms
that nanoceria particles inhibit all forms of reactive oxygen
species (ROS).
For example, the nanoceria particles of the present invention can protect the brain against stroke and reperfusion
injury, the heart cells from effects of cardiac infarction, the
skin from UV rays and bum injuries. Neurodegeneration
(e.g., Alzheimer's, Parkinson's, dementia, amyotrophic lateral sclerosis) and potentially mental retardation (due to loss
of brain cells) within the central and peripheral nervous
systems can also be inhibited. This protection can extend to
diseases which produce chronic problems such as cirrhosis
of the liver or kidney or the multi-organ effects of aging
itself. The nanoceria can become the universal treatment for
all major and minor diseases and events which involve
reactive oxygen species.
The nanoceria (Ce0 2 nanoparticles) have the ability to
destroy toxic products of metabolism known as reactive
oxygen species (ROS). It has been shown in one embodiment that the nanoceria particles prevent the ROS induced
death of mammalian retinal neurons in culture (in vitro) and
subsequently prolonged the life of the cells in culture and

US 7,347,987 B2
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protected the cells from ROS. In the second embodiment,
the ability to provide mammalian cell protection in vivo is
disclosed.
The first embodiment of the present invention provides a
method and composition for promoting the lifespan of
retinal neurons and protecting the nerve cells in the eye from
apoptosis induced by hydrogen peroxide (H 2 0 2 ) in vitro by
decreasing generation of intracellular reactive oxygen species. The treatment of the eye with ultra fine nano-size
cerium oxide is a significant advance in biological uses of
cerium oxide. Persons afflicted with such conditions as,
light-induced retina degeneration and age-related macular
degeneration (AMD) have hope for brighter, clearer vision.
The examples below provide further detail on the preparation and treatment of retinal nerve cells with Ce0 2 nanoparticles.

FIGS. 4A-4H are representative flow cytometry plots of
retinal neurons with and without incubation with Ce0 2
nanoparticles. Measurements were taken after 96 hours. The
cytometry plot shows activity of approximately 10,000 cells
in four quadrants, as described below.
Cl represents the percentage of 10,000 cells showing
Annexin V positive signals, which are interpreted to indicate
the percentage of 10,000 cells undergoing apoptosis.
C2 represents the percentage of 10,000 cells showing both
Annexin V and PI positive signals, which is interpreted as
the percentage of 10,000 cells which are in late apoptotic or
necrotic stage. (Annexin V signals apoptotic stage; PI signals necrotic stage.)
C3 represents the percentage of 10,000 cells showing
neither Annexin V nor PI positive signals, which is interpreted as the percentage of 10,000 cells which are still
viable.
C4 represents the percentage of 10,000 cells showing a PI
positive signal, which is interpreted as the percentage of
10,000 cells in a necrotic stage.
Quadrants C2 and C4 show the percentage of 10,000 cells
committed to die. In quadrant Cl the percentage of 10,000
cells undergoing apoptosis are shown and some may be
salvaged. It is important to observe the percentage of 10,000
cells in quadrant C2 for the efficacy of the cerium oxide
treatment of the present invention.
Focusing on the viable cells, the control in FIG. 4Ahas no
Ce0 2 nanoparticle treatment and 73.9% of the cell population is viable after 96 hours. FIG. 4B is treated with 100 µM
H 2 0 2 , causing a deadly assault and leaving the lowest
percentage (57 .7%) of viable cells. The addition of gradually
increasing concentrations of cerium oxide with 100 µM
H 2 0 2 , are shown in FIGS. 4C-4G.
FIG. 4C is treated with 1 nM Ce0 2 nanoparticles and 100
µM H 2 0 2 and 60.6% of the cell population remains viable.
FIG. 4D is treated with 3 nM Ce0 2 nanoparticles and 100
µM H 2 0 2 and 67.0% of the cell population is viable. FIG. 4E
is treated with 5 nM Ce0 2 nanoparticles and 100 µM H 2 0 2 ,
with 68.9% of the cell population remaining viable. FIG. 4F
is treated with 10 nM Ce0 2 nanoparticles and 100 µM H 2 0 2
and 72.6% of the cell population is viable. FIG. 4G is treated
with 20 nM Ce0 2 nanoparticles and 100 µM H 2 0 2 and
72.3% of the cell population remains viable.
FIG. 4H is treated with 20 nM Ce0 2 nanoparticles without
the addition of H 2 0 2 and 73.4% of the cell population
remains viable showing that the Ce0 2 nanoparticles alone
have no negative effect on the cell population.
The data in FIGS. 4A-4H can also be summarized from
the analysis of cells undergoing apoptosis as shown in
quadrant Cl. The control, FIG. 4A shows 16.2% of cells
undergoing apoptosis under normal conditions, without any
treatment, after 96 hours. FIG. 4B shows 26.1 % of cells
undergoing apoptosis after the 100 µM H 2 0 2 challenge.
FIGS. 4C-4G show there are 28.3%, 21.9%, 22.2%, 18.5%
and 15.8% of cells undergoing apoptosis with 1, 3, 5, 10 and
20 nM Ce0 2 nanoparticle treatment, respectively. FIG. 4H
shows 15.7% of cells undergoing apoptosis with 20 nM
Ce02 nanoparticle treatment, which is a slight improvement
over no treatment at all as shown by the control in FIG. 4A.
Thus, cerium oxide nanoparticles inhibit apoptosis in
retinal neurons in vitro in a dose and time dependent manner.
FIG. 5 shows relative viable retinal neurons with and
without incubation of different concentration of Ce0 2 nanoparticles for different time periods. The concentration of
Ce02 nanoparticles were 1 nM, 3 nM, 5 nM, 10 nM, 20 nM
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EXAMPLE 1
A primary retinal neuron culture is obtained from albino
rat pups. Retinae of Sprague-Dawley albino rat pups (0-2day old) were dissected out and mechanically dissociated in
25 ml of DMEM/F12 medium. After being filtered through
230 µm and 140 µm sieves, the dissociated cells were
centrifuged at 1200 rpm for 5 min. The cell pellets were
re-suspended in the medium to 1xl05 cells/ml. 1 ml of the
cell suspension was plated in each well pre-treated with 10
µg/ml of poly-D-lysine. The cells were maintained in the
medium until day 7, when different concentrations ofCe0 2
nanoparticles were added to the cultures. The timeline for
the addition of Ce0 2 nanoparticles is shown in FIG. 1. The
treated neuronal cells were harvested on day 14, day 19, day
24 and day 29 after the beginning of treatment on day 7. The
percentage of apoptotic retinal neurons in the culture with
and without 5 nM Ce0 2 nanoparticle treatment is shown in
FIG. 2 at the 12th day, 14th day, 19th day, 24th day and 29th
day. Data are shown in M±S.D. Statistics were collected by
Student t-test (n=3, *p<0.05, **p<0.01). FIG. 2 confirms
that at every testing period the control with no Ce0 2
nanoparticle treatment had a higher percentage of apoptotic
retinal neurons in the culture, in contrast to the decreased
percentage of apoptotic retinal neurons in the cells treated
with 5 nM Ce0 2 nanoparticles.
EXAMPLE 2
The detection of apoptosis by flow cytometry is illustrated
in FIGS. 3, 4A-4H and 5. After periods of incubation with
Ce0 2 or H 2 0 2 , the cells were washed with serum free
medium 3 times, followed by treatment of 1 ml of 1xtrypsin
for 2 min. After centrifuging, the cell pellet was resuspended
in 500 µl of lxPBS containing 5 µl of Annexin V-FITC and
25 µl of Propidium Iodide (PI). The kit used for the analysis
is commercially available from Beckman Coulter and is
known as the "ANNEXIN V-FITC Kit." The mixture was
incubated on ice for 10 minutes. The fluorescent emissions
of FITC and PI were detected by flow cytometry (Beckman
Coulter) with the excitation filters of 492 nanometers (nm)
and 550 nm. The FITC fluorescent emissions signals the
presence of cells undergoing apoptosis; whereas, the PI
signals with an automatic red color fluorescence the binding
to DNA fragments identifying cells in a necrotic stage.
FIG. 3 shows a treatment timeline with Ce0 2 incubation
after the 7th day of treatment at the time intervals of 12
hours, 24 hours, 72 hours and 96 hours with each treated
sample subsequently exposed to 12 hours incubation time
with H 2 0 2 .
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each with 100 µM H 2 0 2 ; one sample was treated with only
100 µM H 2 0 2 and another sample was treated with only 20
nM Ce0 2 nanoparticles. The measurement of relative viable
cells for each group was determined after 12 hours, 24 hours,
48 hours, 72 hours and 96 hours. The effects showed dose
and time dependency.
5 nM cerium oxide nanoparticles started to decrease the
apoptosis at 24 h of incubation. As incubation time
increased, the protective effect from 5 nM nanoparticles was
more significantly increased. Additionally, 100 nM and 20
nM nanoparticles began to have effects late with 96 h of
incubation. (Statistical analysis was done by ANOVA, and
Duncan test for post hoc analysis. Data are presented in
M±S.D. n~3, *p<0.05, **p<0.01). FIG. 5 shows that among
the various treatment doses, 5nM Ce0 2 nanoparticle treatment gave the earliest response with moderate protective
effect and 20 nM Ce0 2 nanoparticle treatment gave the
highest protective effect with late response.

a dose and time dependent manner. It has also been determined that cerium oxide nanoparticles decrease generation
of intracellular reactive oxygen species in a dose and time
dependent manner. Thus, the present invention represents a
significant advance in the treatment in degenerative diseases
of the retina, such as, but not limited to light-induced retina
degeneration and age-related macular degeneration (AMD).
In the second embodiment of the present invention a rat
"light damage" model for retinal degeneration was used as
the test system. The data demonstrate that the nanoceria
prevented the death of retinal neurons when given prior to
the "light insult". The nanoceria particles protected the cells
at the time of exposure as well as prevented the subsequent
death seen days later in the untreated animals. The in vivo
route of administration, including, direct injection into the
eye, intravenous, intraperitoneal, intramuscular, oral or topically on the eye or skin may improve the result. Similarly,
the time of administration of the nanoparticle, both before or
after an insult, is important. Thus, the nanoceria will also
prevent the death of retinal cells due to glaucoma, diabetic
retinopathy, inherited retinal degeneration (for example,
Retinitis Pigmentosa), macular degeneration, retinal detachment or any disease or event which proceeds through the
production of ROS. These particles should preserve and
prolong vision when administered in vivo.

EXAMPLE 3
Intracelluar reactive oxygen species (ROS) production
was measured in both Ce0 2 nanoparticle treated and control
cells using 29, 79-dichlorofluorescein diacetate (DCFH-DA,
Sigma). Briefly, the retinal neurons were exposed to Ce0 2
nanoparticles with different concentrations and various incubation times. After incubation, the cells were incubated with
10 µM DCFH-DA (dissolved in dimethylsulfoxide
(DMSO)) at 37° C. for 30 min. The cells then were incubated with 1 mM H 2 0 2 at 37° C. for 30 min after the excess
DCFH-DA was washed with PBS. The cells were harvested
as described above. The intensity of fluorescence was
detected by flow cytometry with the excitation filter of 485
nm. The ROS level was calculated as a ratio: ROS=mean
intensity of treated cells divided by mean intensity of control
cells.
FIG. 6 is an experimental paradigm showing the beginning of the Ce0 2 nanoparticle treatment on the 7th day and
simultaneous incubation with H 2 0 2 and DCFH-DA and a
timeline of exposure at 30 minutes, 12 hours, 24 hours, and
96 hours. FIGS. 7A-7D show how the Ce0 2 nanoparticles
decreased the generation of ROS in a dose and time dependent manner. The ROS generated in the groups of 5 nM, 10
nM, and 20 nM nanoparticle incubation were statistically
significantly less than the group without treatment at the
earliest (12 h) of the tested points. 3 nM nanoparticle
incubation had an effect at 24 h. However, 1 nM nanoparticles did not show any significant decrease within the tested
time point. Statistical analysis was done by ANOVA, and
Duncan test for post hoc analysis. Data were shown in
M±S.D. n=3, ** p<0.01; *p<0.05.
The cerium oxide of the present invention includes those
cerium compounds that have reacted with atmospheric oxygen to have stable oxide layers identified as CeO.sub.nl,
wherein 0 is less than 1 or equal to 2 (0<n1<2) and
(0<n2<3).
The cerium oxide particles of the present invention are
characterized as ultra-fine and are preferably in a size range
of from approximately 1 nanometer in diameter to approximately 10 nanometers in diameter; more preferably from
approximately 1 nm to approximately 7 nm. A judicious
selection of particle size is required by someone skilled in
the art and is not a limitation of the present invention.
The results of testing in the above examples document the
ability of cerium oxide nanoparticles to promote the Iongevity of retinal neurons in vitro and inhibit apoptosis
induced by hydrogen peroxide on retinal neurons in vitro in
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Rats were injected intravitreally with 2 microliters (µ!)of
nanoceria (concentrations from 0.1 to 1.0 micromolar) three
days before they were exposed for six hours to a bright light
(2700 LUX) in a light box. The animals were returned to
normal lighting for 3.5 days, then killed, the eyes enucleated, fixed, processed for paraffin embedding, sectioned, and
either stained with H & E or processed for immunocytochemistry.
The number of photoreceptors remaining was determined
with the H&E sections by using a microscope connected to
a digital camera to record the images and then measuring the
thickness of the outer nuclear layer every 240 microns from
the optic nerve along both the superior and the inferior retina
to the ora seratta. The data was then plotted as retina
thickness versus the distance from the optic nerve head. The
changes in other layers of retinal cells were recorded with
images but not quantified. Cells actively undergoing apoptosis were also visualized using a commercially available
"Apoptosis kit" and recording the microscopic images with
a fluorescence microscope.
The data demonstrate that the nanoceria at all concentrations tested prevented the immediate death of retinal cells
shortly after exposure to light as well as the ongoing death
seen days later in the untreated animals. We therefore have
demonstrated in vivo that these nanoceria particles can
protect cells within the rat retina from light-induced cell
death.
Prior to the present invention, it was not known that
nanoceria particles could be used in vivo for preventing
blindness or death of retinal cells, or for preventing the death
in vivo of any other cell type in any disease. The chemical
properties of Ce02 nanoparticles enable the destruction of
reactive oxygen species (ROS) produced by toxins and/or
products of oxygen metabolism within cells.
Thus, nanoceria can protect any cell type from ROS
induced damages. Diseases which could possibly be prevented, cured or ameliorated would include hereditary blind-
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ness, macular degeneration, glaucoma, diabetic retinopathy,
retinal detachment, and other blinding diseases which
involve ROS would be potentially solved. Similarly, in other
cells within the central nervous system (CNS), neuronal
death in strokes, degenerative diseases such as Alzheimer's
Disease, Parkinson's, Huntington's Disease, and the death
of peripheral nerves are preventable or at least the rate of cell
death can be decreased and would result in prolonged
function of the cells, tissues, organs, and individual.

We claim:
1. A method for promoting longevity of retinal neurons
comprising the steps of: preparing ultra-fine particles of at
least one of Ce0 2 and Ce2 0 3 in concentration of approximately 3 nanomolar (nM) to approximately 50 nanomolar
(nM) and administering said ultra-fine particles to the eye by
direct injection or topically to protect the manimalian body
system from damage to any tissue due to reactive oxygen
species (ROS).
2. The method of claim 1, wherein the ultra-fine particles
have a diameter in a range between approximately 1 nanometer (nm) and approximately 10 nm.
3. The method of claim 1 comprising the step of preparing
ultra-fine particles of Ce0 2 .
4. The method of claim 3, wherein the concentration of
Ce02 is in a range between approximately 3 nanomolar (nM)
and approximately fifty nanomolar (nM).

While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein
are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
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